Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02289898




Registration number
NCT02289898
Ethics application status
Date submitted
10/11/2014
Date registered
13/11/2014
Date last updated
28/09/2020

Titles & IDs
Public title
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Scientific title
A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Secondary ID [1] 0 0
M18-006
Universal Trial Number (UTN)
Trial acronym
YOSEMITE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pancreatic Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Demcizumab
Treatment: Drugs - Abraxane®
Treatment: Drugs - gemcitabine
Treatment: Drugs - Placebo

Experimental: Abraxane® and gemcitabine plus placebo - Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression

Experimental: Abraxane® and gemcitabine plus demcizumab plus placebo - Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression

Experimental: Abraxane® and gemcitabine plus demcizumab - Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression


Treatment: Drugs: Demcizumab
administered intravenously

Treatment: Drugs: Abraxane®
administered intravenously

Treatment: Drugs: gemcitabine
administered intravenously

Treatment: Drugs: Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms
Timepoint [1] 0 0
Investigator-assessed progression-free survival time through duration of the study (2 years, 23 days).

Eligibility
Key inclusion criteria
1. Subjects must have histologically confirmed metastatic pancreatic ductal
adenocarcinoma.. Prior chemotherapy and/or radiotherapy either in the adjuvant or
neoadjuvant setting or for metastatic disease is not allowed.

2. Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue (from either the
primary tumor, locoregional disease or a metastatic site), either fresh
core-needle-biopsied or archived (two FFPE cores preferred whenever possible). If
fresh tissue is obtained, the core biopsy must be done at least 7 days prior to
randomization.

3. Age =21 years

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 5. Measurable
disease per RECIST v1.1

5. Adequate organ and marrow function

6. Signed Informed Consent Form

7. For women of childbearing potential, agreement to use two effective forms of
contraception
Minimum age
21 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subjects with a neuroendocrine tumor of the pancreas, an acinar tumor of the pancreas
or a pancreatic tumor with mixed histologies.

2. Subjects receiving heparin, warfarin, factor Xa inhibitors or other similar
anticoagulants. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal
anti-inflammatory agents.

3. Subjects with brain metastases, leptomeningeal disease, uncontrolled seizure disorder,
or active neurologic disease

4. Subjects with Grade >2 peripheral neuropathy

5. Subjects with clinically significant ascites

6. Malignancies other than pancreatic cancer successfully treated within 3 years prior to
randomization, except for adequately treated carcinoma in situ of the cervix, basal or
squamous cell skin cancer, treated superficial bladder cancer, localized prostate
cancer treated surgically with curative intent, ductal carcinoma in situ treated
surgically with curative intent

7. Significant intercurrent illness that will limit the patient's ability to participate
in the study or may result in their death over the next 18 months

8. History of a significant allergic reaction attributed to humanized or human monoclonal
antibody therapy

9. Subjects with known clinically significant gastrointestinal disease including, but not
limited to, inflammatory bowel disease

10. Pregnant women or nursing women

11. Subjects with known HIV infection

12. Known bleeding disorder or coagulopathy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/04/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2017
Sample size
Target
Accrual to date
Final
207
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Prince of Wales Hospital - Randwick
Recruitment hospital [2] 0 0
Monash Medical Centre, Moorabbin - Bentleigh East
Recruitment hospital [3] 0 0
Western Health (Sunshine Hospitals) - St Albans
Recruitment hospital [4] 0 0
St John of God Murdoch Hospital - Murdoch
Recruitment hospital [5] 0 0
St. John of God Subiaco Hospital - Subiaco
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
3165 - Bentleigh East
Recruitment postcode(s) [3] 0 0
3021 - St Albans
Recruitment postcode(s) [4] 0 0
6150 - Murdoch
Recruitment postcode(s) [5] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
New Hampshire
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
Belgium
State/province [16] 0 0
Brussels Capital
Country [17] 0 0
Canada
State/province [17] 0 0
Alberta
Country [18] 0 0
Canada
State/province [18] 0 0
British Columbia
Country [19] 0 0
Canada
State/province [19] 0 0
Nova Scotia
Country [20] 0 0
Canada
State/province [20] 0 0
Ontario
Country [21] 0 0
Spain
State/province [21] 0 0
Madrid
Country [22] 0 0
Spain
State/province [22] 0 0
Barcelona
Country [23] 0 0
Spain
State/province [23] 0 0
Zaragoza
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Bristol
Country [25] 0 0
United Kingdom
State/province [25] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
OncoMed Pharmaceuticals, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Celgene Corporation
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic
pancreatic ductal adenocarcinoma.

The purpose is to test the efficacy and safety of demcizumab, when given in combination with
gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and
Abraxane® is a standard treatment for patients with metastatic pancreatic ductal
adenocarcinoma.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02289898
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries